The triple-negative breast cancer (TNBC) subtype, defined clinically by the lack of estrogen, progesterone, and Her2 receptor expression, accounts for 10% to 15% of annual breast cancer diagnoses. Currently, limited therapeutic options have shown clinical benefit beyond cytotoxic chemotherapy. Defining this clinical cohort and identifying subtype-specific molecular targets remain critical for n...

s: Vaccination with peptides in IGF-IR that induce robust Th1 immunity with limited immunosuppression significantly inhibit tumor growth in a model of triple-negative breast cancer. Department of Defense Breast Cancer Research Program Era of Hope Meeting, 2011. Vaccination targeting IGF-IR sensitizes tumors to tamoxifen therapy in an anti-estrogen resistant mouse model. American Association of ...

Background & Objective: Our knowledge about correlation of androgen receptor expression and clinicopathological properties of triple-negative breast cancer (TNBC) patients is inadequate, particularly in the Iranian population. The main aim of the present study was to assess the AR expression in TNBC Iranian patients and evaluate its correlation with their clinicopathological pa...

Abstract Purpose of Review Triple-negative breast cancer (TNBC) represents about 15–20% all cancers and often presents as an aggressive with poor prognosis compared to other forms cancer. This article will review the clinical manifestations, imaging features, pathology correlation, treatment management, TNBC. Recent Findings While mammography ultrasound can be used diagnose TNBC, MRI is most ac...